Home » Stocks » BEAT

BioTelemetry, Inc. (BEAT)

Stock Price: $72.25 USD 0.11 (0.15%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 2.48B
Revenue (ttm) 438.83M
Net Income (ttm) 17.68M
Shares Out 34.32M
EPS (ttm) 0.48
PE Ratio 150.52
Forward PE 35.97
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $72.25
Previous Close $72.14
Change ($) 0.11
Change (%) 0.15%
Day's Open 71.91
Day's Range 71.76 - 72.63
Day's Volume 823,771
52-Week Range 28.93 - 72.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

NEW ORLEANS--(BUSINESS WIRE)--Please replace the release dated December 23, 2020 with the following corrected version due to multiple revisions. The updated release reads: BIOTELEMETRY INVESTO...

Zacks Investment Research - 3 weeks ago

Philips (PHG) enters into a deal to acquire BioTelemetry, which drives the expansion of its cardiac care portfolio and fuels customer acquisition.

Other stocks mentioned: PHG
PRNewsWire - 3 weeks ago

NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BioTelemetry, Inc. (NASDAQ: BEAT) concerning...

PRNewsWire - 4 weeks ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioTelemetry, Inc. ("BioTelem...

PRNewsWire - 4 weeks ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

GlobeNewsWire - 4 weeks ago

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Bi...

PRNewsWire - 4 weeks ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by BioTelemetry, Inc. (NASDAQ: BEAT) and its board of directors concerning the prop...

Other stocks mentioned: PHG
Business Insider - 4 weeks ago

BioTelemetry gained as much as 18% on Friday after news that the cardiac-diagnostics firm will be acquired by Dutch company Royal Philips for $2.8 billion. BioTelemetry is a Pennsylvania-based...

Other stocks mentioned: PHG
Business Wire - 4 weeks ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioTelemetry, Inc. (NASDAQ: BEAT) to Royal Philips for $72.00 per share in ...

PRNewsWire - 4 weeks ago

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breac...

GlobeNewsWire - 4 weeks ago

MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT) , the leading remote medical technology company focused on the delivery of health information to improve quali...

Seeking Alpha - 1 month ago

BioTelemetry has had a better than expected third quarter, leveraging new patient uptake plus clinician accounts in their healthcare and continuous care segments. Management have secured bette...

Seeking Alpha - 2 months ago

BioTelemetry's (BEAT) CEO Joseph Capper on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

BioTelemetry (BEAT) delivered earnings and revenue surprises of 15.38% and 7.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Posts Record Quarterly Revenue Amidst Rapid Recovery Posts Record Quarterly Revenue Amidst Rapid Recovery

GlobeNewsWire - 2 months ago

MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time.

Zacks Investment Research - 4 months ago

BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

BioTelemetry's (BEAT) CEO Joseph Capper on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Posts Strong Results and Ramps Up Business Development Activity Posts Strong Results and Ramps Up Business Development Activity

GlobeNewsWire - 5 months ago

Company expands portfolio of solutions with groundbreaking insertable cardiac monitor system Company expands portfolio of solutions with groundbreaking insertable cardiac monitor system

GlobeNewsWire - 5 months ago

Expands relationship to serve Centene members Expands relationship to serve Centene members

GlobeNewsWire - 5 months ago

MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2020 earnings on Thursday, July 30 at 4:00 PM Eastern Time.

Seeking Alpha - 7 months ago

BioTelemetry: Still Undervalued Despite Pandemic Headwinds

Seeking Alpha - 8 months ago

BioTelemetry, Inc. (BEAT) CEO Joseph Capper on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 8 months ago

BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve qual...

GlobeNewsWire - 9 months ago

Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval Only remote cardiac monitoring company whose pr...

Seeking Alpha - 10 months ago

BioTelemetry, Inc. (BEAT) CEO Joseph Capper on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

BioTelemetry: I Foresee Further Share Price Growth Going Into New Year

GuruFocus - 1 year ago

CFA, Chairman andCEO of GAMCO Investors, Inc., Mario Gabelli (Trades, Portfolio), bought shares of the following stocks in both the second and third quarters.

Other stocks mentioned: ABBV, AXTA, AC, ADSW, CARS, GMED, IIN, STI
Seeking Alpha - 1 year ago

BioTelemetry's (BEAT) CEO Dave Bauer on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

BioTelemetry (BEAT) delivered earnings and revenue surprises of 4.00% and 0.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

MALVERN, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve qual...

Seeking Alpha - 1 year ago

Apple's Heart Study disruption continues as the Apple Watch maintains strong growth along with services.

Seeking Alpha - 1 year ago

BioTelemetry Inc. (BEAT) CEO Joseph Capper on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.

Seeking Alpha - 1 year ago

BioTelemetry is doing some great things but will have to stay smart to stay ahead of the competition in a finite market disrupted by new technologies.

Zacks Investment Research - 1 year ago

BioTelemetry (BEAT) closed the most recent trading day at $47.69, moving +1.6% from the previous trading session.

Seeking Alpha - 1 year ago

BioTelemetry Inc. (BEAT) CEO Joseph Capper on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.

Zacks Investment Research - 1 year ago

Bull of the Day: BioTelemetry (BEAT)

Zacks Investment Research - 1 year ago

BioTelemetry: Top Stock Picks for the Week of Apr 22, 2019

Tracey Ryniec and Kevin Cook look at two highly rated stocks.

Zacks Investment Research - 1 year ago

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Healthcare services is the future for Apple as well as for BioTelemetry in its latest acquisitions of Geneva and LifeWatch.

About BEAT

BioTelemetry, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which... [Read more...]

Industry
Diagnostics & Research
IPO Date
Mar 18, 2008
CEO
Joseph Capper
Employees
1,700
Stock Exchange
NASDAQ
Ticker Symbol
BEAT
Full Company Profile

Financial Performance

In 2019, BioTelemetry's revenue was $439.11 million, an increase of 9.92% compared to the previous year's $399.47 million. Earnings were $29.84 million, a decrease of -30.30%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BioTelemetry stock is "Hold." The 12-month stock price forecast is 72.00, which is a decrease of -0.35% from the latest price.

Price Target
$72.00
(-0.35% downside)
Analyst Consensus: Hold